Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus GG is associated with mucin genes expressions in type 2 diabetes mellitus: a randomized, placebo-controlled trial.

  • 2023-03-30
  • European journal of nutrition 62(5)
    • Beyza Eliuz Tipici
    • Ender Coskunpinar
    • Derya Altunkanat
    • Penbe Cagatay
    • Beyhan Omer
    • Sukru Palanduz
    • Ilhan Satman
    • Ferihan Aral

Study Design

Type
Randomized Controlled Trial (RCT)
Sample size
n = 34
Population
34 women, aged 30-60 years with T2DM
Methods
randomized, placebo-controlled trial, 8 weeks of 10×10^9 Cfu/day Lactobacillus rhamnosus GG ATCC 53,103
Blinding
Double-blind
Duration
8 weeks
Funding
Unclear
  • Rigorous Journal

Purpose

Recent studies indicate that dysbiosis of gut microbiota and low-grade inflammation are important pathogenic determinants of type two diabetes mellitus (T2DM). The aim of this study is to investigate the effects of Lactobacillus GG on glycemic control, lipid profile, inflammatory parameters, and some gene expression levels in individuals with T2DM.

Methods

In a randomized, placebo-controlled trial, 34 women, aged 30-60 years with T2DM consumed daily probiotics or placebo for 8 weeks. The probiotic group consumed 10 × 109 Cfu/day Lactobacillus rhamnosus GG ATCC 53,103 (LGG), approved by the TR Ministry of Food, Agriculture, and Livestock. Anthropometric measurements, food diary, fasting blood, and fecal samples were taken at baseline and post-treatment.

Results

Fasting blood glucose was significantly decreased in probiotic (p = 0.049) and placebo (p = 0.028), but there was no difference between the groups. In the probiotic group, no significant difference was observed in HbA1c, fructosamine, lipid profile, and inflammatory variables compared to baseline. In this group, with LGG supplementation, mucin 2 and 3A (MUC2 and MUC3A) gene expressions increased more than ninefolds (p = 0.046 and p = 0.008, respectively) at post-treatment. Meanwhile, there was no significant change in any of the gene expressions in the placebo group. There was no significant difference in energy, protein, dietary fiber, and cholesterol intakes between placebo and probiotic groups during the study. However, daily fat intake (p = 0.003), body weight (p = 0.014), and body fat (p = 0.015) in the probiotic group were significantly decreased.

Conclusion

In this study, the effects of a single probiotic strain were investigated for 8 weeks. At the end of the study, although there was no finding that clearly reflected on the glycemic parameters of T2DM, its beneficial effects on the expression of mucin genes, which are responsible for weight loss and protection of intestinal barrier functions, cannot be denied. Further studies are needed to reveal the importance of these findings.

Clinical trial registration

ID: NCT05066152, October 4, 2021 retrospectively registered in ClinicalTrials.gov PRS web site.

Research Insights

  • Lactobacillus rhamnosus GG→Improved Blood Lipid Profile

    In the probiotic group, no significant difference was observed in HbA1c, fructosamine, lipid profile, and inflammatory variables compared to baseline.

    Effect
    Neutral
    Effect size
    Small
    Dose
    10 × 10^9 Cfu/day
  • Lactobacillus rhamnosus GG→Improved Mucin 2 Gene Expression

    In this group, with LGG supplementation, mucin 2 and 3A (MUC2 and MUC3A) gene expressions increased more than ninefolds (p = 0.046 and p = 0.008, respectively) at post-treatment.

    Effect
    Beneficial
    Effect size
    Large
    Dose
    10 × 10^9 Cfu/day
  • Lactobacillus rhamnosus GG→Improved Mucin 3A Gene Expression

    In this group, with LGG supplementation, mucin 2 and 3A (MUC2 and MUC3A) gene expressions increased more than ninefolds (p = 0.046 and p = 0.008, respectively) at post-treatment.

    Effect
    Beneficial
    Effect size
    Large
    Dose
    10 × 10^9 Cfu/day
  • Lactobacillus rhamnosus GG→Reduced Body Fat

    daily fat intake (p = 0.003), body weight (p = 0.014), and body fat (p = 0.015) in the probiotic group were significantly decreased.

    Effect
    Beneficial
    Effect size
    Small
    Dose
    10 × 10^9 Cfu/day
  • Lactobacillus rhamnosus GG→Reduced Body Weight

    daily fat intake (p = 0.003), body weight (p = 0.014), and body fat (p = 0.015) in the probiotic group were significantly decreased.

    Effect
    Beneficial
    Effect size
    Small
    Dose
    10 × 10^9 Cfu/day
  • Lactobacillus rhamnosus GG→Reduced Fasting Blood Glucose Levels

    Fasting blood glucose was significantly decreased in probiotic (p = 0.049) and placebo (p = 0.028), but there was no difference between the groups.

    Effect
    Neutral
    Effect size
    Small
    Dose
    10 × 10^9 Cfu/day
  • Lactobacillus rhamnosus GG→Reduced Fructosamine

    In the probiotic group, no significant difference was observed in HbA1c, fructosamine, lipid profile, and inflammatory variables compared to baseline.

    Effect
    Neutral
    Effect size
    Small
    Dose
    10 × 10^9 Cfu/day
  • Lactobacillus rhamnosus GG→Reduced Hemoglobin A1c

    In the probiotic group, no significant difference was observed in HbA1c, fructosamine, lipid profile, and inflammatory variables compared to baseline.

    Effect
    Neutral
    Effect size
    Small
    Dose
    10 × 10^9 Cfu/day
  • Lactobacillus rhamnosus GG→Reduced Inflammatory Markers

    In the probiotic group, no significant difference was observed in HbA1c, fructosamine, lipid profile, and inflammatory variables compared to baseline.

    Effect
    Neutral
    Effect size
    Small
    Dose
    10 × 10^9 Cfu/day
Back to top